Expert Insights On Decentralized Trials

  1. The Rise, Fall, And Eventual Rebound Of DCTs 3/25/2024

    First there was skepticism, then enthusiasm, and then disillusionment. DCTs have had their ups and downs. Here, we're looking ahead to the future of DCTs.

  2. Post-Pandemic Planning: Using Direct-To-Patient Deliveries For Supply Chain Management 2/23/2024

    UCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.

  3. 4 Things I Learned At SCOPE 2024 2/21/2024

    The Summit for Clinical Ops Executives (SCOPE) ran from Feb. 11-4. Discover four things Executive Editor Abby Proch learned at the annual event.

  4. 4 Things I'm Looking Forward To At SCOPE 2024 2/1/2024

    The Summit for Clinical Ops Executives (SCOPE) begins Feb. 11. Discover four things Executive Editor Abby Proch is looking forward to at the annual event.

  5. 3 Ways Biotechs Can Lower The Cost Of Clinical Trials 1/23/2024

    LongeVC has identified three innovative models to help biotechs lower the cost of their clinical trials.

  6. The 3 Big Downsides To DCTs 1/8/2024

    James Gillespie, Ph.D., and Gregory Privitera, Ph.D. discuss three overlapping categories of concern when it comes to DCTs: consent and selection, user experience, and comfort and privacy.

  7. What Clinical Trial Experts Think Will Happen With DCTs In 2024 12/28/2023

    In part three of this preview of clinical trials trends, experts discuss the state of decentralized trials in all their permutations and muse on their fates as we enter 2024. 

  8. Can DCTs Be Both Patient Centric And Financially Efficient For Sites? 9/22/2023

    While DCTs have the potential to provide more convenience and improved access for patients, the anticipated cost savings touted for these trials have yet to materialize fully at the site level. In fact, the opposite has occurred in some instances.

  9. Decentralization: It's More Than You Think 7/26/2023

    Decentralization is not only a breakthrough in trial design but also in the larger field of scientific research and represents a paradigm shift in the digital world. It drives patient empowerment, trial accessibility, and new fundraising models. 

  10. Advancing Rare Disease Research With Patient Registries 6/16/2023

    In this Q&A, “Rare dad” Harsha Rajasimha, Ph.D. of IndoUSrare discusses the current state of rare disease research and explains how patient registries can help propel drug development for rare disease therapies.